The combination of anti-PD-1 (7mg/kg) and Alphataxin (10 mg/kg) decreased tumor growth or induced tumor regression of the implanted renal adenocarcinoma cells suggesting these doses and treatment schedule are sufficiently efficacious. This evidence concerns the gene PDCD1 and papillary renal cell carcinoma.